The prevalence of hepatitis C virus (HCV) genotype 4 has increased throughout Europe. This is an epidemiological study of patients infected chronically with HCV genotype 4 in Denmark. The HCV strains analyzed originated from patient samples collected between 1999 and 2007 as part of the national Danish hepatitis B and C network, DANHEP. Sequence analyses were based on the envelope 1 region of HCV. Results from a total of 72 patients indicated a high degree of genetic heterogeneity. Fifty-six patients (78%) were infected with one of the three dominating subtypes: 4d, 4a, or 4r. The remaining 16 patients (22%) were infected with subtypes 4h, 4k, 4l, 4n, 4o, or 4Unclassified. Three epidemiological profiles were identified: (1) Patients infected with HCV by intravenous drug use were infected solely with subtype 4d. They were all of European origin, and 15 of the 16 patients were ethnic Danes. No single transmission event could be confirmed, but the pairwise nucleotide identity within the patients of Danish origin was relatively high (~95%), suggesting a recent introduction into Denmark. (2) The 21 patients infected with subtype 4a all came from Northern Africa, Egypt, Pakistan, or the Middle East. (3) Patients from Southern Africa dominated among patients infected with subtype 4r (10 of 12 patients). This study demonstrates that HCV genotype 4d has been introduced in and spread among Danish intravenous drug users. The remaining subtypes show restricted distribution, infecting almost exclusively patients from geographical areas with a relatively high prevalence of HCV genotype 4 infections.
INTRODUCTION
Hepatitis C virus (HCV) is currently one of the most widespread infectious viruses, with more than 170 million people infected worldwide [WHO, 1999] . About 65-85% of individuals with acute HCV infection develop a chronic infection, with risk increased significantly of developing liver cirrhosis and hepatocellular carcinoma [Hoofnagle, 1997; Seeff, 2002] . The HCV virion contains a single-stranded, positive-sense RNA genome and has been classified into the Hepacivirus genus of the Flaviviridae family. The HCV genome is very heterogeneous, as reflected both by genome length and by the identification of seven major genotypes and more than 67 subtypes with nucleotide divergences of 31-33% and 20-25%, respectively [Bukh et al., 1994; Simmonds et al., 2005; Kuiken et al., 2008; Kuiken and Simmonds, 2009 ]. Genotypes 1, 2, and 3 are found worldwide, particularly in Western countries. Genotypes 4 and 5 display a more restricted geographic pattern with high prevalences in the Middle East and Africa. Egypt has the highest prevalence of HCV; 20% of the Egyptian population is chronically infected with HCV, and among this group, almost 90% are infected with genotype 4 [Kamal and Nasser, 2008] . Genotype 6 is mainly found in Southeast Asia, and genotype 7 has been found in patients of African origin living in Canada and Belgium .
Although infection with all HCV genotypes can progress to chronic liver disease, genotype-specific differences in the natural history of the disease may exist. For example, HCV genotypes 1 and 3 have been found to induce steatosis [Cross et al., 2010] . The efficacy of the standard treatment with ribavirin and pegylated interferon depends on the genotype, with infection with either genotype 1 or 4 leading generally to a poorer treatment response than infection with genotype 2 or 3 [Fried et al., 2000; Fabiani, 2007] .
Within HCV genotype 4, there is a widespread genetic heterogeneity, which is reflected by the presence of at least 19 subtypes (4a-h, 4k-4u) according to the Los Alamos HCV Database [Kuiken et al., 2005] . The overall prevalence of genotype 4 among the general population of patients infected with HCV in the United States and Europe is thought to be low. Two U.S. studies done 10 years apart reported a low prevalence (approximately 1%) of genotype 4 [Lau et al., 1996; Nainan et al., 2006] . A Slovenian study found a genotype 4 prevalence of 1.4% among a large cohort of 1,504 patients infected with HCV [Seme et al., 2009 ]. A fourfold increase in the prevalence of genotype 4 during a five-year period was reported among older patients with sporadically acquired infection in Calabria, Southern Italy [Matera et al., 2002] . It is of note that the first identified subtype 4d strain was isolated from a Danish patient in 1993 [Bukh et al., 1993] .
Although HCV genotype 4 seems to constitute a rather low percentage of patients infected with HCV in the Western world, it has spread throughout Europe, especially among intravenous drug users. In Greece, genotype 4 is the second most frequent genotype among intravenous drug users [Savvas et al., 2005] , and similar results were obtained in a study from Southern Spain [Sánchez-Quijano et al., 1997] . In Southwestern France, a genotype 4 prevalence of 7.4% was found, with subtypes 4a and 4d identified almost exclusively among intravenous drug users (99%) [Nicot et al., 2005] . In the Netherlands, a study using a molecular epidemiological approach identified genotype 4 in three different epidemiological profiles. One group was found to be correlated to Egypt, one to intravenous drug users, and one with men who have sex with men [de Bruijne et al., 2009] 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Serum Institut were found to harbor genotype 4. Patients were genotyped with genotypespecific primers located in the 5' HCV non-coding region, as described previously [Krarup et al., 1998; Krarup et al., 2000] . (5): 72°C (30 seconds); steps 3-5 were repeated 39 times. Final extension was carried out at 72°C for 10 minutes followed by 30 minutes at 4°C.
PCR products were sequenced with the primers "Inner C-E1 F" and "Inner C-E1 R"
using the BigDye Terminator v3.1 Cycle Sequencing Kit and the ABI 3130x sequencer (Applied Biosystems, Foster City, CA, USA). Primers used were from a study published previously [Ray et al., 2000] and have been shown previously to have equal sensitivity against isolates of the different HCV genotypes [Corbet et al., 2003] . Sequences were aligned and edited manually using the SeqScape Software v2.6 (Applied Biosystems, Foster City, CA, USA) and BioEdit Software [Hall, 1999] . Multiple alignments of the patient and reference sequences were carried out with ClustalX software v. 1.8 [Thompson et al., 1997] .
To ensure an equal length of all included sequences, the phylogenetic analysis was based on a subdomain of the E1 region from nucleotides 923-1202, with nucleotide positions relative to the HCV H77, genotype 1a reference strain [Kolykhalov et al., 1997 ]. The phylogenetic tree was inferred by the neighbor-joining (NJ) method using the Kimura 2parameter correction distances with bootstrap values based on 1,000 replicates ( Fig. 1) . To ensure the strength of the phylogenetic analysis, a multiple sequence comparison by logexpectation (MUSCLE) alignment with a maximum number of iterations equal to 2 was carried out [Edgar, 2004] . A maximum likelihood tree was built with PHYML using the HKY85 substitution model and bootstrapped with 100 replicates [Guindon and Gascuel, 2003 ]. The reference strains included in the phylogenetic tree are named with genotype/subtype and country of origin when possible, otherwise with sampling country and the GenBank accession numbers (Fig. 1 ). Reference sequences were included for genotype 1 [Kolykhalov et al., 1997] , genotype 2 [Kato et al., 2001] , genotype 3 [Sakamoto et al., 1994] , and genotype 4 [Bukh et al., 1993; Stuyver et al., 1994; van Doorn, 1994; Fujimura et al., 1996; Ray et al., 2000; Morice et al., 2001; Lavillette et al., 2005; Brown et al., 2007; Franco , 2007; Hmaied et al., 2007; Timm et al., 2007; Kuntzen et al., 2008; Demetriou et al., 2009; Khan et al., 2009] . 
Epidemiology of the Patients with Genotype 4
Almost 70% of patients with chronic infection with HCV genotype 4 were males (Table I) .
The median age was 49.5 years (interquartile range (IQR) 40-59 years) (Table I) . The phylogenetic N-J tree of the partial E1 sequences (Fig. 1) 4d patients, plus one patient of unknown origin; these clusters were not supported, however, by significant bootstrap values (Fig.1) . For patients infected with other subtypes, the route of Table II ) than subtype 4d (P = 0.0044) and subtype 4a (P = 0.013) patients. The median ages in the latter two groups were comparable (4d, median: 45 years, IQR: 41-51.5 years; 4a, median: 51 years, IQR: 37.75-58 years, P = 0.588).
Pairwise Identity and Similarity of Patient Sequences with Published Sequences
The similarity between the patient nucleotide sequences (subtypes 4a, 4d, 4r, and 4UN) and
published nucleotide sequences was investigated using BLAST, and each closest match for 4a, 4d, 4r, and 4UN was retrieved. All of the subtype 4d patient strains were most similar to a published genotype 4d sequence isolated from an African patient (FJ462437). The average pairwise nucleotide identity within the entire group of subtype 4d patient strains was 94.2%
(64-99%); within the Danish patient strains, it was 94.9% (91-99%). The different subtype 4a patient strains were most similar to various sequences: an isolate from a Pakistani patient (AB444559), an isolate from a Yemeni patient (D43681), an isolate from an Egyptian patient (DQ988079), an isolate published from the United States (DQ418787), and an isolate published from Japan (D45193).
The pairwise nucleotide identity within the entire group of subtype 4a patients was 87%
(67-93%); within the Egyptian patient group, it was 85.4% (69-93%). The pairwise nucleotide identity within the subtype 4r patient strains was 91.3% (86-96%), and 11 of the 12 patients were most similar to two Yemeni isolates (D43681, D43678). In the five cases of unclassified subtype (4UN), two of the patient strains were most similar to sequences from Canada (EF115910) and Cyprus (EU684694), one was related to a strain from Canada (EF115886), one was situated between subtypes 4a and 4n, and one was situated between 4e and 4q. Neither the BLAST investigation nor comparison against the HCV Los Alamos Database yielded further subtype information.
HCV/HIV Co-infection
Of the 47 patients who were tested for HIV, 9 were HIV positive (19.2%) and 38 (80.8%)
were HIV negative (Table I) . Of the 72 patients, 25 (34.7%) had not been tested.
Among patients co-infected with HIV, the known routes of HCV transmission were intravenous drug use and sexual contact. One patient co-infected with HCV/HIV was a man having sex with men and self-reported to have been infected by sexual contact with a former partner from Germany. No single HCV genotype 4 subtype dominated among patients coinfected with HCV and HIV (Table II) .
DISCUSSION
This nationwide study of patients infected with genotype 4 identified three epidemiological profiles. HCV subtype 4d was found in an ethnic Danish patient for the first time in 1993 [Bukh et al., 1993] [Schröter et al., 2002; et al., 2003] . As expected, all of the eight Egyptians included in the study (Table II) were infected with subtype 4a [Elkady et al., 2009 ]. The 4a sequences from these patients did not cluster, and the nucleotide divergence 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ranged widely, explained possibly by the early introduction and exponential spread of this subtype in Egypt [Tanaka et al., 2004] .
The third epidemiological profile was found for patients with subtype 4r. This subtype was found mostly among Southern African patients, and these patients were significantly older than patients infected with subtypes 4d and 4a (64 years versus 45 and 51 years, respectively, Table II ). Though not supported by significant bootstrap values, nine Southern African patients and one Southern European patient along with the GenBank reference strains D43681, D43679, and D43678 seemed to form a monophyletic cluster. Subtype 4r has been described previously in patients of Central African origin: A Canadian study found a prevalence of 10.2% of subtype 4r among patients mostly of Central African origin Ndong-Atome et al., 2008] . The nucleotide variation within subtype 4r patient strains is between that of subtypes 4d and 4a. However, the molecular epidemiology of HCV in Africa is documented poorly, and the number of African 4r sequences available publicly is small [Ndong-Atome et al., 2008] . A high prevalence of HCV genotype 4 has been found in the Central African Republic, but the prevalence of subtype 4r was low (5%) [Njouom et al., 2009 ].
Five African patients were infected with unclassified subtypes (4UN). Two of these patients were men of Northern African origin and clustered with GenBank reference strains of unclassified subtypes, EU684694, and a Canadian strain, EF115910, isolated from a patient originating from Rwanda (Fig. 1) . Unclassifiable genotype 4 strains have been described in African patients [Ndong-Atome et al., 2008] . These new sequences could form a new subtype, genetically closely related to subtypes 4q, 4e, and 4l, but to determine this, more sequence data are needed. In addition, the unclassified strains were sequenced in NS5B and analyzed phylogenetically, with results showing a similar distribution of the sequences as found for E1 (data not shown). BLAST analysis of the remaining 4UN patient strains did not identify a subtype.
The subtypes infecting the patients co-infected with HCV and HIV varied, and no particular genotype 4 subtypes dominated (Table I) . The HCV subtype 4d sequences from coinfected patients did not cluster together, and there was no indication of a connection between these patients. In addition, there were no significant differences between the prevalence of HCV/HIV co-infection among the genotype 4 patients (19.2%) in this study and the prevalence of HCV/HIC co-infection among the entire group of DANHEP participants, which included patients of all genotypes (17.9%), (P = 0.4153).
In conclusion, this population from Denmark seemed to display a subtype distribution pattern similar to that found earlier in other Western countries, but with a more restricted distribution of subtypes in relation to ethnic origin [Nicot et al., 2005; Cantaloube et al., 2008] . Genotype 4 has been established and spread among men who have sex with men in Europe, an epidemiological profile not found in Denmark. The subtypes 4d, 4a, and 4r dominate among patients who are infected chronically with HCV and living in Denmark.
This study has shown that subtype 4d as a single subtype has been introduced in and spread among Danish intravenous drug users with chronic HCV. In general, the strains among Danish patients infected with chronic HCV genotype 4 are very heterogeneous genetically.
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